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Objective: To determine whether more “modern” complex wound dressings further improve the healing of venous ulcers
over that with simple wound dressings, we conducted a systematic review of randomized controlled trials (RCTs) of
wound dressing trials that were published from October 1, 1997, through September 1, 2005.
Methods: We searched MEDLINE, CINAHL, and the Cochrane Controlled Trials Registry Database to identify RCTs.
Criteria for ultimate selection included treatment with compression and an objective outcome describing the proportion
of wounds healed. Twenty RCTs were identified that satisfied these criteria and were classified into three wound dressing
classes: semiocclusive/occlusive group (n  8), growth factor group (n  7), and human skin equivalent group (n  5).
Results: Assessment of study design quality for the 20 RCTs showed a low percentage (<49%) of RCTs that incorporated
at least 3 of 7 indicators of trial quality, but it seemed better in the 5 RCTs that showed significance for ulcer healing; 4
of the studies used at least 6 of the 7 characteristics of adequate study design. Five (25%) of the 20 RCTs had a statistically
significantly improved proportion of ulcers healed in the experimental dressing group over control values: zinc oxide paste
bandage (79% vs 56%) and Tegasorb (59% vs 15%) in the semiocclusive/occlusive group and perilesional injection of
granulocyte-macrophage colony-stimulating factor (57% vs 19%) and porcine collagen derived from small-intestine
submucosa (Oasis; 55% vs 34%) in the growth factor group. In the sole significant RCT from the human skin equivalent
group, Apligraf (63%) was superior to Tegapore (48%). Four of these five studies also showed an improved time to
complete healing by Kaplan-Meier estimate.
Conclusions: Certain wound dressings can improve both the proportion of ulcers healed and the time to healing over that
achieved with adequate compression and a simple wound dressing. The selection of a specific dressing, however, will
depend on the dressing characteristics for ease of application, patient comfort, wound drainage absorption, and expense.
(J Vasc Surg 2006;44:1118-25.)Leg ulcers due to chronic venous insufficiency are a
painful and disabling condition with significant chronicity—
nearly one half of the limbs experience an ulcer recurrence
within a decade. The associated direct cost of ulcer treat-
ments for a patient amounts to approximately $30,000 per
year in the United States, and in some industrialized coun-
tries, this outlay may represent approximately 1% of the
total health care budget.1 A Cochrane Systemat i c Review
has shown that high levels of compression with a multi-
layered system are most effective, and this is associated
with an ulcer healing rate of 60% to 80% at 6 months.2
Several practice guidelines for the treatment of chronic
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1118venous ulcer have recommended that a simple nonadherent
wound dressing be used in combination with compression
bandaging.3
The advantages of any additional treatment modality
that could improve both the proportion of venous ulcers
healed and their healing time would have a profound
socioeconomic effect, but such benefits for more complex
“modern” wound dressings for venous ulcers are unclear.
For example, a systematic review of randomized controlled
trials (RCTs) commissioned by the UK National Health
Service Health Technology Assessment (HTA) program in
1999 identified 48 wound dressings RCTs for venous leg
ulcers but concluded that major methodologic flaws were
an issue affecting the validity of most of the studies.4
The efficacy of a new wound dressing should be vali-
dated through an RCT that is sufficiently powered and that
also uses current standards of care, especially adequate
external compression, as well as a contemporary wound
dressing in the control arm.5 Objective outcomes with the
proportion of wounds completely healed and their healing
rates should be provided.6 Toward that end, we conducted
a systematic review of all wound dressing RCTs for venous
ulcers published since the last HTA review. Our review will
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proved proportion of ulcers healed and, where available,
the time to complete healing—and (2) quality of trial
design in RCTs that examined newer wound dressings. The
purpose of this systematic review is twofold: to guide the
clinician toward RCT-validated new wound dressings that
improve ulcer healing and to underline certain study design
issues that should be addressed in future trials.
METHODS
As an extension of a systematic review of RCTs, which
were performed to assess what was the “usual care for
wounds” with wound dressings as the specific goal of that
study,5 we especially focused on outcomes from the exper-
imental arm of wound dressing trials for chronic venous
ulcer. Therefore, our review began with articles published
since October 1, 1997 (the concluding time of the HTA
review), and carried through to September 2005. We
searched for English-language studies in MEDLINE,
CINAHL, and the Cochrane Controlled Trials Registry.
General inclusion criteria. A chronic venous ulcer
was defined as an ulcer that fails to heal completely after
receiving standard medical treatment for at least 30 days.5
RCTs that evaluated the treatment of chronic venous ulcers
with any number of human subjects were included. Ex-
cluded from this review, however, were ulcers that were
defined as “mixed” in etiology, ie, a combination of arterial
and venous causes. Most studies that were reviewed had
noninvasive vascular laboratory examinations to exclude
occult arterial occlusive disease. Nonrandomized compar-
ative studies and cohort studies were excluded. In addition,
we excluded RCTs that failed to define clearly a control or
experimental group. Studies that focused primarily on com-
pression therapy rather than a wound dressing for venous
ulcers have been reviewed by the Cochrane systematic
review and are not included in this review.
Treatment criteria. Given the demonstrated benefi-
cial effects of compression, only wound dressing studies
that reported compression in both arms of the study were
included in our review. Our aim was to isolate the effect of
a new wound dressing on the healing of venous ulcers.
Outcomes criteria. The Food and Drug Administra-
tion (FDA) draft guidance document for industry6 and the
HTA document4 outlined important criteria for both trial
design and outcomes that should be used in the assessment
of wound care technologies. The primary outcome was the
proportion of wounds completely healed (entirely epitheli-
alized) over the trial period, whereas another important
secondary outcome was the time to complete wound heal-
ing, determined by Kaplan-Meier analysis. Partial wound
healing, including change in wound size, may be used as
supportive evidence for the beneficial biological effect of a
product or procedure,4,5 but this outcome is not an accept-
able substitute for complete wound healing and is not used
in this review.4,5 Therefore, studies that failed to report
complete wound healing within the study period were
excluded from this review. Finally, the incidence of ulcerrecurrence was also sought in this review but was not a
criterion by which a study could be included or excluded.
Classification of wound dressings. This analysis modi-
fied a general classification of wound dressings patterned
after Winter,7 who categorized wound dressings by the
degree of activity with the wound: passive, interactive, and
active dressings. For the purposes of our review, wound
dressing types were divided into nonocclusive and three
experimental groups: the semiocclusive/occlusive (SOC)
group, the growth factor (GF) group, and the human skin
equivalent (HSE) group. The first two dressing classes
(nonocclusive and SOC groups) are based on the degree
that the wound dressing reduces both water vapor and heat
loss from the wound, which has been shown to improve
both the incidence and the healing time of wounds.7 The
GF group includes those dressings that directly provide a
GF or indirectly stimulate important growth substances
within the wound, whereas the HSE provides both wound
coverage and potential GFs for wound healing. Although
nonocclusive dressing types might be used occasionally in
the control arm, the experimental arm of the RCTs re-
viewed in this study focused on the SOC, GF, or HSE
groups. To rationalize the individual dressing types, the
British National Formulary has used the products’ proper-
ties and mode of action as a classification system.8 This is
particularly helpful in subcategorizing the broad groups of
SOC dressings. The dressing classification used in this
review was merely to group wound dressings with a similar
biological mechanism and not to test the superiority of one
dressing class over another.
Assessing the methodologic quality of the study.
The methodologic quality of each RCT was assessed by
using desirable characteristics of clinical trials as outlined in
the FDA document6 and as recommended for future dress-
ing trials in the conclusions of the HTA report4: (1) a priori
sample size calculation, (2) single reference wound, (3)
baseline comparability of study groups, (4) detailed de-
scription of concurrent treatments (eg, debridement, other
dressings, and compression type), (5) blinded assessment of
outcomes, (6) intention-to-treat analysis, (7) number of
and reasons for patient withdrawals, and (8) survival anal-
ysis of wound healing.
Analysis of treatment effects. Trials that met the
inclusion criteria were grouped according to their mode of
biologic action: SOC, GF, and HSE. The risk ratio of
treatment failure (nonhealing of ulcers) and the corre-
sponding 95% confidence interval were calculated from
data reported in the original studies, and these results are
shown in Figs 1 to 3. Seven of eight trials in the SOC group
compared different types of SOC with each other, and no
two studies within this category performed the same com-
parison. By contrast, in the HSE group, the various types of
dressings in the experimental group being evaluated were
deemed to be too heterogeneous to be combined in a
meta-analysis to give a meaningful overall estimate. There-
fore, these two groups were analyzed qualitatively, and
meta-analyses were not performed. Both the interventions
used in the treatment groups and in control groups in the
botto
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analysis was performed by using a random-effects model to
estimate an overall effect.9 A random-effects model incor-
porates both within-study and between-study heterogene-
ity, so this method provides a wider confidence interval
(more conservative) when heterogeneity is present.
RESULTS
We identified 68 potentially relevant RCTs of chronic
venous ulcers. Sixteen RCTs that dealt with intravenous or
intramuscular drug therapy or mechanical treatment of
venous ulcers (eg, ultrasonography or high-voltage cur-
Fig 1. Plot of individual studies of semiocclusive dressi
heterogeneity. CI, confidence interval.
Fig 2. Meta-analysis of growth factor studies. The blac
treatment failures and their respective 95% confidence int
line in the center of the figure represents the RR of 1
experimental and the control groups. A confidence inter
of this study is not statistically significant. For growth
estimate and its corresponding 95% CI are shown at therent) and an additional 19 that failed to include compres-sion were eliminated, so 33 articles were selected for
detailed review. The “proportion of wounds healed” out-
comewas not reported in 13 additional RCTs, so 20 studies
ultimately formed the basis of this review. Nine studies
were in the SOC group: seven in the GF group and five in
the HSE group.
Study demographics. The number of patients in-
cluded in the trials varied significantly, ranging from 18 to
293 (mean, 95). Few studies clearly provided the exact time
period over which patients were accrued. The mean age for
each individual RCT had a bimodal distribution, with nine
(45%) trials in the 50- to 60-year-old age group and eight
mparisons. Meta-analysis was not performed because of
les and the horizontal lines depict the risk ratios (RR) of
(CI) of the studies included in each analysis. The vertical
re there is no difference in the outcome between the
at crosses this no-difference line indicates that the result
r trials, a meta-analysis was performed, and the overall
m of the figure.ng cok circ
ervals
, whe
val th
facto(40%) in the 71 to 80 age group. In the SOC group, six of
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ratio was 1:1 in half of the studies, and an equal number of
the remainder had either a 2:1 male-female ratio or a 1:2
male-female ratio.
Elements of usual care. Only half of the trials re-
ported that wound debridement was performed as a com-
ponent of wound care. The highest proportion of RCTs
that described this factor was in the HSE group (4/5); this
may be related to wound bed preparation for the biological
dressing. Although the form of compression was quite
varied, two studies failed to specify the actual type of
compression. Only one study used an Unna boot alone as
the principal means of compression. The remaining studies
used forms of compression that have been defined as in the
class III category (British National Formulary): maximal
compression.8
The type of dressing used in the control group may
have been influenced by the type of dressing being evalu-
ated in the experimental group. Nonadherent (n  7),
hydrocolloid (n 4), and foam (n 3) dressings were the
most frequently used dressings in the control groups (Figs
1-3), whereas a zinc paste bandage was used in three trials.
Hydrocolloid or foam dressings were used more frequently
in the SOC group (6/8), whereas nonadherent dressings
were used more frequently in the GF group (4/7). The
frequency of dressing changes was usually dependent on
the dressings being studied. Eight of 20 wound dressing
types were changed once per week, whereas in 5 studies the
dressings were changed twice per week. There seemed to be
no difference by experimental dressing type.
Two studies in the HSE category used a form of skin
graft in their control group—one a meshed split-thickness
skin graft and another of cryopreserved keratinocytes—
which may have been similar in effect to the experimental
dressing. In addition, seven studies in the SOC group
selected a dressing in the same class (SOC) for their control
group.
Study length. Approximately half of the trials were of
12 weeks’ duration. Four were shorter: one was 10 days,
another three were eight weeks, and three were 4 months.
Fig 3. Plot of individual studies of human skin equivale
heterogeneity. CI, confidence interval.Two studies with the longest trial periods were conductedover 6 and 9 months. The last trial, Stacey and colleagues’
trial,10 is usually prolonged for studies of this type and
perhaps as a result had the highest proportion of wounds
healed in the “control” groups.
Methodologic quality of the studies. Most of the
trials examined the efficacy of a new commercial wound
dressing product, but only nine reported a role of industry
participation or industry support of the study. In addition,
all 20 RCTs were reviewed for methodologic quality (Ta-
ble). Eight trials performed an a priori calculation of the
number of trial participants required, and most of these
trials were in the GF group (Table). Baseline comparability
of subjects regarding such characteristics as ulcer size and
duration was evident in most studies, particularly in the
SOC group, but other influential characteristics were fre-
quently lacking, such as the status of the deep system.
Blinding of outcomes was reported in 7 trials, and all 20
studies used a single reference wound. As defined by the
selection criteria for our analysis, each study was required to
use an objective outcome (the proportion of wounds
healed), but only 10 (50%) studies reported the healing
rate. The number of patients who dropped out of a study
and the reason for the withdrawal were stipulated in 17
of 20 studies. However, only seven studies performed
intention-to-treat analysis.
Studies significant for improved healing. The five
trials that showed a statistical advantage for a specific
wound dressing were analyzed for their adherence to seven
factors of study design. The Oasis and Apligraf studies
incorporated all seven elements of a properly designed
study, whereas the Stacey10 and DaCosta12 studies incor-
porated six of the seven elements. Limova and Troyer-
Caudle’s11 study that compared two types of hydrocolloids
reported on only two elements.
OUTCOMES
Proportion of wounds healed. Five (25%) of the 20
RCTs reported statistically significant improvement in the
proportion of ulcers healed (totally epithelialized within the
time frame of the study) in the experimental group com-
mparisons. Meta-analysis was not performed because ofnt copared with the control group. Stacey et al10 showed that at
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customary dressing, Viscopaste (a zinc oxide–paste impreg-
nated bandage with a 79% wound healing rate), was supe-
rior to either a zinc oxide–impregnated stockinette (59%)
or a calcium alginate fiber dressing (56%) (P  .05). Li-
mova and Troyer-Caudle11 found that over 8 weeks, 59%
of the wounds healed in the Tegasorb group vs a 15%
healing rate in the patients treated with another hydrocol-
loid, Duoderm (P .03). In addition, Tegasorb was supe-
rior in the absorption of exudate and patient comfort.
In the three GF group studies that showed significance,
two complex treatment regimens, one with granulocyte-
macrophage colony-stimulating factor administered by pe-
riulcer injection12 and the other with vasoactive intestinal
peptide delivered by iontophoresis,13 were associated with
57% and 37% healing rates, respectively, in contrast to the
approximately 18% healing rate in both control groups.
When the data provided in the Gherardini study13 were
analyzed for significance, however, it failed to achieve sta-
tistical significance, in contrast to that of DaCosta et al12
(P .014). Therefore, the Gherardini study was eliminated
from those that achieved efficacy for the experimental
group. Mostow et al14 recently completed a multicenter
trial in which collagen derived from porcine small-intestinal
submucosa (Oasis) was compared with the foam dressing
Allevyn over 12 weeks. Of the wounds in the Oasis group,
55% healed, in contrast to 34% of the wounds in the Allevyn
group (P  .02). Finally, Falanga15 conducted a large
multicenter trial with 309 participants (293 ultimately
treated) over a much longer trial period than the other
trials: 6 months. The investigators used a complex applica-
tion schedule wherein five applications of Apligraf (alloge-
neic cultured HSE) were allowed in the first 3 weeks of the
trial if less than 50% of the wound surface was covered by
Apligraf. A 63% healing rate was observed in the experi-
mental group, in contrast to a 49% healing rate in the
Tegapore-treated control group (P  .02).
Analysis of treatment effects. The risk ratios and
confidence intervals of the treatment failure of the individ-
ual studies for SOC and HSE are shown in Figs 1 and 3.
Meta-analyses for these two groups were not performed
because of heterogeneity of the comparison groups. The
results of themeta-analysis and for the individual studies for
Table. Elements of study design (quality)
Variable
Semiocclusive/occlusive
(n  8)
A priori calculation 1
Comparability of baseline characteristics 7
Single reference wound 8
Number of and reason for dropouts 8
Intention-to-treat analysis 2
Survival rate analysis of time to wound
healing 7
Blinding 2
HTA, Health Technology Assessment.treatment failure for the GF trials are shown in Fig 2. Asmentioned previously, we recognize the diversity of dress-
ing types within this group.
Healing rates to complete wound healing. One half
of the RCTs reported healing rates in median days to
complete healing: three of the eight studies in the SOC
group, four of the seven studies in the GF group, and three
of five studies in the HSE group. Stacey et al10 demon-
strated a reduction in median days to complete healing
from zinc oxide paste over both calcium alginate and zinc
oxide stockinette by Cox regression (P .001). One of the
studies that had shown statistical advantages for the exper-
imental group in the proportion of ulcers healed,11 how-
ever, did not provide a healing rate. In three studies in
which no significant difference in the proportion of ulcers
healed was observed, a similar outcome was noted in heal-
ing rate—no difference. In the GF group, DaCosta et al12
showed a significantly improved healing rate (control, 112
days; experimental, 54 days), as did Mostow et al14 (con-
trol, 95 days; experimental, 70 days; P  .023), which
paralleled both investigators’ results with the proportion of
ulcers healed. In contrast, two studies showed no difference
in healing rates, similar to their findings with the propor-
tion of ulcers healed. Finally, Falanga et al15 observed a
shortening of the time to complete closure from 181 days
in the control group to 61 days in the Apligraf group (P 
.003), a finding that was not observed in the two other
groups that recorded this finding.
Recurrence. Only four of the trials provided data on
ulcer recurrence, and this was based on a short follow-up
period. Therefore, it was impossible to assess the benefits of
a dressing on preventing recurrence.
DISCUSSION
Chronic venous ulcers of the lower extremity produce
significant disability and pain for the affected patient and
are associated with both daily and recurring expenditures
for the usually prolonged ambulatory care.1 The funda-
mentals of nonsurgical treatment are based on (1) external
compression, which preferably achieves a compression
pressure of 40 mm Hg,2 and (2) care of the wound.1 There
is skepticism as to whether more sophisticated wound
dressings can improve on the results with ulcer healing that
are achieved with adequate compression and simple wound
th factor
 7)
Human skin equivalent
(n  5)
Total (N  20),
n (%)
1999 HTA
review4 (%)
5 2 8 (40) 6
7 3 17 (85) 60
7 5 20 (100) —
6 3 17 (85) 53
4 1 7 (35) 13
4 2 15 (75) —
5 0 7 (35) 18Grow
(ndressings alone: 89% of ulcers healed in a recent trial were
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compression in both arms of the trial as well as a contem-
porary wound dressing in the control arm can determine
the efficacy of a new “complex” wound dressing. Our
systematic review of 20 RCTs that satisfied these criteria for
ulcer care and used the objective outcome of the propor-
tion of ulcers healed at the end of the trial demonstrated
that only 5 of these trials (25%)—and less than 10% of the
studies originally identified—had a significantly improved
proportion of ulcers healed. Each of the five successful
RCTs used optimal compression with four-layer bandages
or class III stockings, so that the results in the experimental
arm should represent the additive effect of a complex
wound dressing combined with a maximal compression
regimen.
Modern wound dressings have evolved from the older
concept of leaving the wound dry and covered by a
protective dressing to a new concept.31 Semiocclusive or
occlusive wound dressings prevent evaporative water loss
from the wound and retain warmth—favorable factors for
improved wound healing. These dressings, however, vary
in their ability to control and absorb both the amount and
composition of wound drainage. Also examined in this
review was the type of wound dressings that provide or
stimulate factors that are necessary for wound healing and
have been touted as “miracle dressings.”32 These dressings
have been claimed by their advocates to accelerate the
healing process. Finally, HSE dressingsmay provide epider-
mal coverage of the wound. This coverage is usually tem-
porary, but this dressing type’s mechanism of action also is
to supply/stimulate important GFs to the wound.33 Cer-
tainly, each dressing class differs in several factors: the
simplicity with which it is applied, the frequency of required
dressing changes, absorption of wound drainage, expense,
and comfort to the patient.
One unusual dressing in the GF group involves periulcer
injection of granulocyte-macrophage colony-stimulating
factor.12 This complex method of administration may lead
to a lower adoption clinically, particularly if cost, patient
comfort, and reasonable results with alternative dressings
are considered. Regarding another dressing in the GF
group, however, a recent large multicenter RCT showed
that a collagen dressing derived from porcine small-
intestinal submucosa (Oasis) at 12 weeks had both a statis-
tically significant improvement in the number of ulcers
healed and a reduced time to wound closure.14 Like SOC,
the Oasis dressing is relatively easy to apply to the wound.
Finally, in the largest multicenter trial reviewed in our
analysis (293 subjects), Falanga et al15 showed that Apligraf
promoted improved ulcer healing. In a subsequent post
hoc analysis of the “hard to heal ulcers” subgroup from this
trial, the authors suggested that Apligraf was particularly
advantageous in ulcers of long duration, which are notori-
ously unresponsive to usual care. It is important to empha-
size that we focused on the individual RCTs that improved
healing and recognize that the dressings within each class
and the attendant confounding variables make it impossible
to define one wound dressing group as superior.Study design. In assessing the studies as a whole, flaws
in study design (Table), which had been pointed out pre-
viously in the 1997 HTA analysis, were still evident.4 Only
40% of the studies performed an a priori calculation of the
number of subjects required to achieve statistical signifi-
cance, and a similar proportion had small study populations
of fewer than 50 subjects. Obviously, these shortcomings
make it difficult to prove convincingly the efficacy of a new
dressing.
Wound dressing characteristics of the control group.
A usual principle of study design is that the control group
should use a treatment regimen reflective of contemporary
wound management, such as simple dressings or paste
bandages. This type of control dressing should show a clear
difference, if it exists, in wound healing compared with the
experimental dressing. As previously mentioned, the use of
an SOC dressing in the control group, which can be con-
sidered an advanced form of contemporary wound man-
agement, may have blurred the potential differences in the
seven or eight RCTs in the SOC group, in which one SOC
dressing was compared with another within the same dress-
ing class. In several of the SOC studies the authors appeared
to be assessing a specific characteristic of the wound dress-
ing, e.g. number of dressing changes required, as their
primary outcomes. As a result, the comparison of the
proportion of ulcers healed became a secondary outcome.
Comparability, of the proportion of ulcers healed in the
experimental and the control group rather than superiority
allowed the study to focus on the dressing characteristics. It
is interesting to note that SOC dressings were used as
controls in the studies of Mostow et al14 (foam) and
Falanga et al15 (film). Similar problems with the choice of
the control dressing were observed in two other trials in the
HSE group, in which a dressing that was similar in biolog-
ical action to the experimental dressing was used.28,29
Again, this choice may mitigate against showing healing
advantages for the experimental group and may have been
selected to show comparability.
Other details of wound care. There was a lack of
specificity in these RCTs for other aspects of direct wound
care that may influence ulcer healing.5 Only 50% of the
studies indicated that debridement was performed, which is
an important independent factor influencing the healing of
diabetic foot ulcers34 and, now, venous ulcers.35 The fre-
quency of dressing changes was detailed in all five signifi-
cant RCTs. Although the frequency of dressing changes
was standardized in most studies, the Apligraf study used a
flexible regimen during the first 3 weeks of the trial. If less
than 50% of the wound surface was covered by the bilayered
skin substitute, then the Apligraf could be applied up to five
times during the first 3 weeks.15 This methodological vari-
ation leads to differences in the number of times a specific
treatment is applied. Finally, the type of compression was
specified in detail for most trials. All five trials that showed
an increased proportion of ulcers healed used class III
compression.8 This factor is essential in evaluating the
effect of the dressing alone and controlling for the impor-
tant variable of compression.
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recognized characteristics that influence ulcer healing.
Some studies placed a limit on the size of the ulcer admitted
to the trial and attempted to control for this factor by
excluding large ulcers. Blinding of wound evaluation
seemed difficult to achieve in most RCTs because of the
clues provided by the distinct characteristics of most exper-
imental dressings. Although the number of and reason for
study dropouts were described in 85% of the studies (Table)
and in all five studies that showed significance, intention-
to-treat analysis was used in only 35% of all trials. Four of
the five significant trials, however, used this important trial
design feature. The intention-to-treat principle deals with
the problems of study subject dropouts, who, if excluded
from the experimental arm, could result in elimination of
subjects with factors that could affect the outcome inde-
pendently of the treatment.
When the seven desirable characteristics of study design
are totaled for each of the five trials that showed significance
for ulcer healing, Limova11’ (2/7) seems the weakest in
quality of study design. By contrast, the other four trials
had at least six of these seven characteristics in their trial
design.10,12,14,15 Few trial designs, however, had a feed-in
period that eliminated ulcers that might promptly respond
to conventional treatment.6
Outcome measures. To qualify for admission into this
systematic analysis, the RCT was required to use the objec-
tive outcome measure of proportion of ulcers healed. This
eliminated 13 trials. This criterion for wound healing has
been recommended in both the 1997 HTA analysis4 and
the FDA guidance document,6 and its value has been best
stated in the former:
The unambiguity of complete healing and its importance
to clinicians and patients alike (because of its potential
impact on quality of life and burden of care), make it the
preferred outcome measure with which to compare stud-
ies of clinical effectiveness.4
Time to complete healing introduces the element of dura-
tion of treatment until the ulcer is healed and is usually
derived from a Kaplan-Meier calculation. Three quarters of
the 20 studies included this outcome (Table), and in 4 of
the 5 significant studies, time to healingmatched the results
with the proportion of ulcers healed. This parameter pro-
vides further validation of the superiority of one dressing
over its comparator and signifies that the dressing does
accelerate ulcer healing.
Only four studies reported ulcer recurrence over an
extremely short follow-up period. As a result, a meaningful
interpretation of a dressing’s preventative features is impos-
sible. Moreover, in contrast to surgery or compression, it is
difficult to ascribe a long-term preventative role to a wound
dressing—a belief held by a recent Centers for Medicare
and Medicaid Services panel on wound healing.5
Venous ulcer article. Since the HTA review of study
quality of RCTs for leg ulcers published in 1999 demon-
strated major flaws in study design, our review shows that
there has been some moderate improvement in trial meth-odology (Table). The proportion of studies performing an
a priori calculation of sample size increased from 6% in the
HTA review to 40% in this review. The RCTs in our review
continue to use too small a sample size; only 6 RCTs (30%)
contained 100 or more subjects, and only 1 (5%) contained
more than 200. By contrast, the sample size of the present
ESCHAR (Effect of Surgery and Compression on Healing
and Recurrence of Venous Ulcer Study) trial (500 limbs)
stands in contrast to the current RCTs reviewed. Wound
size was recorded in all RCTs reviewed in this study.
Although reporting of the number of and reason for with-
drawals has improved by 30%, only a moderate increase in
the use of intention-to-treat methodology was observed.
Similarly, blinding of wound assessment was also low. The
comparison of HTA data with the current data underlines
the importance of using better study methodology: RCT
protocols for venous ulcer have a way to go.
Ideal study protocol. Wound trials should be multi-
center to recruit a sufficient number of patients to ensure
comparability of groups at baseline. Baseline characteristics
that may influence the healing of a venous ulcer should be
described in detail, eg, the status of the deep venous system.
The randomization procedure should be clearly stated, as
should the inclusion/exclusion criteria. A single reference
wound should be used, and a contemporary wound dress-
ing such as a hydrocolloid should be used in the control
group. Details of concurrent treatments and secondary
dressings, as well as the type and degree of compression,
should be given. Both complete wound healing within the
trial period and the time to complete healing (by Kaplan-
Meier analysis) should be provided. Although enumeration
of the number of and reasons for dropouts is clear, intention-
to-treat analysis should be used. Assessment of results
should be blinded to the type of treatment. Ideally, quality-
of-life assessment and cost-effectiveness should be included
along with standard assessment of the effectiveness of a
wound dressing.
CONCLUSIONS
A systematic review of wound dressing RCTs for
chronic venous ulcer identified 20 studies with objective
outcomes of ulcer healing. Five (25%) of these RCTs
showed an increased proportion of ulcers healed at the end
of the study and a reduced time to healing over the control
arm. Because both arms used class III compression, these
five dressings improved ulcer healing. Whereas the 20
RCTs as a whole had a low number of the elements of
proper study design, the 5 RCTs with improved ulcer
healing used at least 4 of 7 of these features. In addition to
efficacy, the ultimate choice of a specific wound dressing
will depend on patient comfort, wound drainage capabili-
ties, ease of use, and expense.16-29
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